Glyn Moody explains an example of patent product hopping

Glyn Moody:

known as “product hopping”. That’s where:

“a company makes modest changes to a product to extend its patent protections so that other companies cannot enter the market and offer less-expensive generic alternatives”…

why Reckitt would want to pay for and then publicize a study that showed one of its own products was dangerous became clearer just a few hours later, when it submitted a “citizen petition” to the Food and Drug Administration:

“urging the US regulator to ban any future competitor pills to its suboxone tablets that were insufficiently “child resistant”.”

In other words, Reckitt effectively wanted the FDA to ban any generic versions of its own tablets, now out of patent, while leaving its patented film formulation on the market to enjoy a new monopoly…